ADC Therapeutics S.A.
ADCT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.03 | -0.04 | 0.06 |
| FCF Yield | -5.43% | -7.90% | -37.44% | -10.46% |
| EV / EBITDA | -15.60 | -3.80 | -15.82 | -4.35 |
| Quality | ||||
| ROIC | -13.54% | -17.06% | -13.17% | -13.22% |
| Gross Margin | 92.68% | 95.56% | 91.05% | 91.89% |
| Cash Conversion Ratio | 0.72 | 0.43 | 1.46 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -15.02% | -25.18% | -25.37% | -30.38% |
| Free Cash Flow Growth | -23.01% | 57.44% | -157.94% | 13.13% |
| Safety | ||||
| Net Debt / EBITDA | 4.28 | 3.54 | -9.93 | 6.79 |
| Interest Coverage | -2.31 | -3.40 | -2.33 | -2.72 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 0.05 | 0.12 | 0.07 |
| Cash Conversion Cycle | 868.55 | 1,002.16 | 205.11 | 131.63 |